Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification
Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.
United States Pooja Advani Mayo Clinic Comprehensive Cancer Center Science Summit Triple Negative Breast Cancer Targetable Mutations
Source: onclive.com